Are measures and related symptoms of cachexia recorded as outcomes in gastrointestinal cancer chemotherapy clinical trials?
Ross ValaireFrances L GardenValentina Razmovski-NaumovskiPublished in: Journal of cachexia, sarcopenia and muscle (2024)
Cachexia-related outcomes were under-recorded in gastrointestinal cancer chemotherapy trials. As trial patients experience a high symptom burden, cachexia-relevant measures and symptoms should be assessed throughout the trial, and integrated with primary endpoints to support their progress.
Keyphrases
- clinical trial
- papillary thyroid
- phase iii
- end stage renal disease
- phase ii
- study protocol
- squamous cell
- chronic kidney disease
- ejection fraction
- locally advanced
- newly diagnosed
- peritoneal dialysis
- open label
- randomized controlled trial
- lymph node metastasis
- type diabetes
- sleep quality
- squamous cell carcinoma
- risk factors
- insulin resistance
- young adults
- childhood cancer
- radiation therapy
- adipose tissue
- depressive symptoms
- skeletal muscle
- rectal cancer
- drug induced